Bristol Myers Squibb has raided AstraZeneca to find its next chief medical officer, persuading Cristian Massacesi, M.D., to ...

A phase 2 trial of Memo Therapeutics’ kidney transplant drug candidate has missed its primary endpoint, adding to the list of ...

Roche’s move came against a backdrop of wider industry retreat from gene therapy, with Pfizer pulling its FDA-approved ...

GLP-1 blockbusters like semaglutide and tirzepatide are widely used for diabetes and weight loss but come with some nasty ...

Adicet Bio is handing out pink slips to 30% of its staffers in tandem with a pipeline restructure that includes discontinuing ...

Australian life sciences venture capital firm Brandon Capital has closed its largest fund yet, raising A$439 million (about ...

Ikena and Inmagene have selected Kristin Yarema, Ph.D., to lead the company upon the anticipated closing of their merger.

Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor ...

Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new ...

The company’s TYK2 inhibitor GLPG3667 sits on the chopping block as well. Galapagos is “actively exploring partnership ...

Roche has obtained European approval for a blood test to help rule out Alzheimer’s disease, allowing patients to avoid ...

Olympus has teamed up with Revival Healthcare Capital to launch a joint venture aimed at bringing robotics to ...